Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hospira/Celltrion: Don't Let U.S. Biosimilar Law's Questions 'Percolate'

This article was originally published in Scrip

Executive Summary

Questions raised in an ongoing lawsuit filed by Amgen involving Novartis unit Sandoz's Zarxio (filgrastim-sndz) about the notice of commercial marketing provision in the Biologics Price Competition and Innovation Act (BPCIA) are vital to the competition and functioning of the multibillion dollar biosimilars industry and should not be allowed to "percolate" and must be answered now, Hospira and Celltrion said in a brief filed on Sept. 3.

Advertisement

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC029677

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel